Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay


ABSTRACT
Regulators of G-protein signaling (RGS) proteins are important components of signal transduction pathways initiated through G-protein-coupled receptors (GPCRs). RGS proteins accelerate the intrinsic GTPase activity of G-protein α-subunits (Gα) and thus shorten the time course and reduce the magnitude of G-protein α- and βγ-subunit signaling. Inhibiting RGS action has been proposed as a means to enhance the activity and specificity of GPCR agonist drugs, but pharmacological targeting of protein-protein interactions has typically been difficult. The aim of this project was to identify inhibitors of RGS4. Using a Luminex 96-well plate bead analyzer and a novel flow-cytometric protein interaction assay to assess Gα-RGS interactions in a high-throughput screen, we identified the first small-molecule inhibitor of an RGS protein. Of 3028 compounds screened, 1, methyl N-[4-(chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimidoate (CCG-4986), inhibited RGS4/Gαi binding with 3 to 5 μM potency. It binds to RGS4, inhibits RGS4 stimulation of Gαi GTPase activity in vitro, and prevents RGS4 regulation of μ-opioid-inhibited adenylyl cyclase activity in permeabilized cells. Furthermore, CCG-4986 is selective for RGS4 and does not inhibit RGS8. Thus, we demonstrate the feasibility of targeting RGS/Gα protein-protein interactions with small molecules as a novel means to modulate GPCR-mediated signaling processes.

Inhibition of signaling networks through disruption of protein-protein interactions presents unique new targets for the development of chemical tools and for possible therapeutic drug discovery (Arkin and Wells, 2004; Pagliaro et al., 2004). Whereas extracellular ligand binding domains, ion channels, and enzyme active sites are considered more “drugable,” blockade of signaling per se generally stops all function. In contrast, inhibition of regulatory protein-protein interactions allows manipulation of distinct steps of a signaling cascade or modifies subcellular targeting, which should permit more subtle pharmacological effects. Activated G-protein-coupled receptors (GPCRs) turn on signaling by inducing GTP exchange for GDP on Gα subunits, which then undergo an activating conformational change releasing free α- and βγ-subunits to cause downstream events, such as channel opening, control of adenylyl cyclase, or hydrolysis of phosphoinositides (Gilman, 1987). Upon hydrolysis of the bound GTP, the Gα subunit returns to its inactive, GDP-liganded form, and its signaling functions are terminated. The hydrolysis of GTP due to the Gα subunit’s intrinsic GTPase activity is very slow but is accelerated up to 1000-fold by regulators of G protein signaling (RGS) proteins (Mukhopadhyay and Ross, 1999; Lan et al., 2000). The GTPase accelerating protein (GAP) activity of RGS proteins (Mukhopadhyay and Ross, 1999; Lan et al., 2000). The GTPase accelerating protein (GAP) activity of RGS proteins shortens the lifetime and, in general, reduces the magnitude of signaling by both the active Gα and the free Gβγ as Gα/Gβγ reassociation occurs rapidly upon formation of the Gα-GDP complex (Neubig et al., 1994). In addition to their GAP activity, RGS proteins can competitively inhibit effector coupling by Gα subunits (Hepler et al., 1997). Of the 20 classic RGS proteins, 19 act on Gαi family G-proteins, whereas at least 12 act on Gαs family signaling (Traynor and Neubig, 2005). Loss of RGS function in vivo leads to markedly altered GPCR signaling (Heximer et al., 2003b; Rahman et al., 2003; Fu et al., 2006; Huang et al., 2006).

ABBREVIATIONS: GPCR, G-protein-coupled receptor; FCPIA, flow cytometry protein interaction assay; RGS, regulator of G-protein signaling; GAP, GTPase accelerating protein; CCG-4986, methyl N-[4-(chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimidoate; CCG-2046, 3-methyl-3-propylcyclopropane-1,1,2,2-tetracarbonitrile; RT, room temperature; DMSO, dimethyl sulfoxide; cv, column volume; DAMGO, [D-Ala²,N-Me-Phe³ Gly⁵-ol]-enkephalin; BCB, bead-coupling buffer; AC, adenylyl cyclase; buffer A, HEPES and dithiothreitol; [³⁵S]GTPyS, guanosine 5’-O-[γ³⁵S]triphosphate.
The RGS proteins have been proposed as novel drug targets (Zhong and Neubig, 2001; Neubig and Siderovski, 2002; Cho et al., 2004; Liebmann, 2004; Riddle et al., 2005) because the utility of targeting GPCRs directly is the basis for the development of many therapeutics. Furthermore, evidence is mounting that RGS proteins may play a role in disease states such as schizophrenia (Mirmics et al., 2001; Williams et al., 2004; Erdely et al., 2006), Parkinson’s disease (Tekumalla et al., 2001; Kovoor et al., 2005; Ding et al., 2006), hypertension (Heximer et al., 2003a; Riddle et al., 2006), and addiction (Traynor and Neubig, 2005). Inhibiting a specific RGS would potentiate the action of natural or exogenous agonist ligands. Moreover, it could enhance the tissue specificity of broadly active agonist ligands by selectively increasing receptor action in tissues that express that particular RGS protein (Zhong and Neubig, 2001). RGS specificity for discrete Gα subunits could also permit a pathway-specific enhancement of agonist action (Zhong and Neubig, 2001; Neubig and Siderovski, 2002).

Small-molecule inhibitors of RGS proteins would be useful tools for dissecting the role of RGS proteins and may provide a first step toward the development of therapeutics. Previous work from our laboratory identified a cyclic octapeptide derived from the RGS interaction site of Gα subunits that inhibits RGS4 and alters G protein-coupled inwardly rectifying potassium channel current kinetics in atrial cells (Jin et al., 2004; Roof et al., 2006). Another group performed a small-molecule RGS inhibitor screen using a yeast two-hybrid readout (Young et al., 2004) that yielded some low-affinity inhibitors, but no structures or follow-up information was reported.

Therefore, our aim was to identify small molecules that inhibit RGS4 activity. However, the standard biochemical assay for RGS protein function is cumbersome and not appropriate for high-throughput screening, because it involves a single-turnover assay of [32P]GTP hydrolysis using a charcoal precipitation step. We chose to measure the high-affinity protein-protein interaction between purified Gα subunits and RGS proteins when the Gα subunit is in the transition-state conformation induced by GDP and AlF4−. We used a flow cytometry protein interaction assay (FCPIA) approach based on previous studies measuring Gα and βγ subunits interactions (Sarvazy et al., 1998) and ligand-receptor-G-protein interactions (Sklar et al., 2002; Simons et al., 2003).

Using FCPIA, we screened a 3028-compound library from the Chembridge screening collection to identify inhibitors of the RGS4/Gαi protein-protein interaction. This screen resulted in five potential RGS4 inhibitors, two of which had IC50 values less than 10 μM. One compound, CCG-4986, inhibited RGS4 GAP activity and RGS4 activity on μ-opioid receptor-mediated signaling. In addition, CCG-4986 is selective for RGS4 compared with RGS8, the most closely related RGS family member (Neubig, 2002). Thus, we report the first small-molecule RGS inhibitor, which should prove a useful tool for studying their role in GPCR signaling.

Materials and Methods

Materials. Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), Fisher Scientific (Hampton, NH), or Acros Organics (Geel, Belgium) and were reagent grade or better. Avidin-coated microspheres for flow cytometry were purchased from Luminex (Austin, TX). [32P]GTP and [35S]GTPγS were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). The screening compound library was from the Chembridge screening collection (http://www.hit2lead.com), and the identity and purity (>96%) of CCG-4986 was confirmed by liquid chromatography/mass spectrometry through the University of Michigan Department of Pharmacology Mass Spectrometry Facility. Three separate batches of CCG-4986 were obtained to complete these studies, each with NMR analysis through Chembridge that verified its structure. Tissue culture media, G418 (Geneticin), fetal bovine serum, and trypsin were purchased from Invitrogen (Carlsbad, CA). DAMGO was obtained through the Narcotic Drug and Opioid Peptide Basic Research Center at the University of Michigan (Ann Arbor, MI). Digitonin was obtained from Gallard-Schlesinger (Plainview, NY). cAMP kits were purchased from Diagnostic Products (Los Angeles, CA). Data were analyzed using Prism 4.0 (GraphPad Software, San Diego, CA).

RGS Protein Expression and Purification. N-terminally truncated (initiating at Met19) rat RGS4, designated pQE60RGS4short (Krumins et al., 2004), was used for the experiments in this study.1 The ΔN-variant was selected because it expresses higher levels of soluble protein in Escherichia coli compared with full-length RGS4. The protein was prepared essentially as described in Krumins et al. (2004). After lysis and centrifugation, the supernatant was applied to a 70-ml S Sepharose Fast Flow (GE Healthcare, Little Chalfont, Buckinghamshire, UK) fast-performance liquid chromatography column. The column was washed with 3 column volumes (cv) of buffer A (50 mM HEPES and 1 mM dithiothreitol, pH 7). A two-stage linear gradient was run, with 0 to 20% buffer B (buffer A + 1 M NaCl) in 3 cv and 20 to 55% in 13 cv. RGS4 eluted in a single broad peak between 290 and 380 mM NaCl. Purified RGS4 was isolated using a Superdex 75 PG gel-filtration column. A glutathione transference-tagged rat full-length RGS8 was purified according to Lan et al. (1998).

Expression and Purification of Gαi. 6X-His-tagged Gαi was expressed and purified from transformed BL21-DE3 E. coli as described previously (Lee et al., 1994). Activity of purified Gαi was determined by [35S]GTPγS binding (Sternweis and Robishaw, 1984).

Chemical Biotinylation of Purified RGS Proteins. RGS proteins were biotinylated with amine-reactive biotinamidohexanoic acid N-hydroxysuccinimide ester (mol. wt., 454.54; Sigma) in a 2:1 (biotin/RGS) stoichiometry. Biotin-N-hydroxysuccinimide ester (1 mg) was resuspended, with sonication, in 1 ml of double-distilled H2O; 40 μl (100 nmol) was added to 1 mg of ΔN-RGS4 (~50 nmol) in a total volume of 300 μl of HEPES buffer (50 mM HEPES, 1 mM EDTA, and 100 mM NaCl, pH 8), and incubated, rotating, at 4°C. The reaction was terminated with 10 μl of 1 M glycine, and excess biotin was removed by applying the sample to a 1-ml Sephadex G25 spin column and eluting with HEN buffer.

Fluorescent Labeling of Gαi. Purified Gαi was chemically labeled with Alexa Fluor 532 carboxylic acid succinimidyl ester (Invitrogen) at a 3:1 fluorophore/protein ratio. Purified Gαi (500 μg, 12.5 nmol) was diluted in 250 μl of H2O to 100 nM (50 mM HEPES, 100 mM NaCl, pH 8) buffer supplemented with 10 μM GDP. Then, 2.8 μl (~38 nmol) of an Alexa Fluor 532 solution (1 mg/100 μl of DMSO) was added, and the suspension was incubated at 4°C in the dark for 1.5 h. The reaction was quenched with 20 μl of 1 M glycine for 30 min. Excess fluorophore was removed via a 1-ml Sephadex G25 spin column and elution with HEN buffer supplemented with GDP. The activity and effective concentration of Gαi was determined after labeling using [35S]GTPγS binding (Sternweis and Robishaw, 1984).

FCPIA and High-Throughput Screen. Each test compound was spotted in 1 μl of DMSO into individual wells of 96-well Axygen polymerase chain reaction plates using a Beckman BioMek FX robot.

1The RGS4-short was found to be indistinguishable from a full-length 6X-His-tagged RGS4 with regard to inhibition of activity or Gαi binding by CCG-4986.
Identification of Small-Molecule Inhibitors of RGS4 171

Intrinsic Fluorescence Measurements. Fluorescence experiments were performed on a Photon Technology International AlphaScan Spectrofluorometer (Photon Technology International, Lawrenceville, NJ) with 2.5-nm slits using wavelengths of 285 and 340 nm for excitation and emission, respectively. ΔN-RGS4 (2 μM) in 600 μl of buffer (20 mM HEPES, 100 mM NaCl, 500 μM Tris(2-carboxyethyl)phosphate) was added to a 5-mm cylindrical quartz cell with micro stir bar. The baseline reading was allowed to stabilize for 2 min, after which 1-μl injections of a 1.2-M solution of CCG-4986 in 50% DMSO/50% buffer were added every 30 s from a Hamilton syringe. Dose-response measurements were carried out over 10 min, with final concentrations of CCG-4986 between 1.9 and 31 nM. For control experiments, the DMSO solvent for CCG-4986 was injected with RGS4, or CCG-4986 was added to a solution of tryptophan, following the same procedure and concentration steps.

Results

FCPIA Measurements of the RGS4/Gαo Protein-Protein Interaction. FCPIA consists of three key components (Fig. 1, A and B): 1) avidin-coated microspheres; 2) biotinylated RGS4; and 3) activated Gαo labeled with Alexa fluor 532. For the experiment, biotinylated RGS4 coupled to avidin-coated beads is coincubated in a 96-well plate with AlF4-activated Gαo (Berman et al., 1996). Samples from each well are aspirated into the Luminex flow cytometer, the bead is detected and bead-associated fluorescence is measured, providing a quantitative reading of the amount of Gαo bound to RGS4. Figure 1C demonstrates several strengths of this method for high-throughput screening. Only the activated Gαo incubated with microspheres precoupled to RGS4 resulted in high-affinity, saturable Goα binding. The Kd value for specific binding was 4.7 ± 0.4 nM (n = 4, in duplicate). The relatively high affinity of the RGS4-Goa interaction in the presence of AlF4 and the very low background fluorescence provide an outstanding signal-to-noise ratio and permit the use of very low concentrations of the protein reagents (2 nM RGS4 and 0.4–100 nM AF532-Gao), demonstrating the suitability of FCPIA for high-throughput screening.

High-Throughput Screen for RGS4 Inhibitors. Our high-throughput screen focused on identifying compounds that bound to RGS4 and disrupted its binding to Gαo. The library consisted of 3028 small-molecule compounds from the Chembridge collection. RGS4 and activated Gαo were added to the plates, and 100 beads/events per well were read on the Luminex flow cytometer. The extremely high S/N of the assay (Z' score of 0.74) permitted the use of small numbers of bead events to reduce reagent use and to speed data acquisition. The screen produced a number of hit compounds as defined by 50% inhibition of the protein-protein interaction signal (Table 1). Five were confirmed in follow-up concentration-response studies, and two compounds, CCG-2046 and CCG-4986, reduced the RGS4-Gαo interaction signal with single-digit micromolar IC50 values (Fig. 2).

Inhibitory Effect of CCG-2046 and CCG-4986 on the Catalytic GTPase Accelerating Activity of RGS4. We tested our two most potent hits in a single-turnover GTPase assay (Lan et al., 1998). Figure 3 shows the ability of RGS4 to accelerate the hydrolysis of GTP by approximately 50-fold compared with the intrinsic Goα GTPase activity. Furthermore, 10 μM CCG-4986 inhibited the catalytic activity of RGS4 by 68%, as measured by this single-turnover experiment. This is consistent with the 71% inhibition predicted

(continued)
from the 4.2 \( \mu M \) IC\(_{50} \) value in the RGS4/G\(_{\alpha} \) binding experiment. It is surprising that CCG-2046 did not inhibit the GTPase activity of RGS4, identifying it as a false positive in our screen.

**Effect of CCG-4986 on RGS4 Intrinsic Tryptophanyl Fluorescence.** The inhibition of G\(_{\alpha}/\)RGS4 binding and GAP activity could be due to an interaction of compound with

<table>
<thead>
<tr>
<th>Table 1: High-throughput screening results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Chembridge library</td>
</tr>
<tr>
<td>Primary hits (( &gt; 50% ) inhibition)</td>
</tr>
<tr>
<td>Confirmed hits</td>
</tr>
<tr>
<td>IC(_{50} ) &lt; 10 ( \mu M )</td>
</tr>
<tr>
<td>Inhibit RGS4 GAP activity</td>
</tr>
</tbody>
</table>

**Fig. 2.** Dose-response curves for two CCG compounds using FCPIA. Two nanomolar concentration of biotinylated RGS4 was coupled to LumAvidin microspheres and preincubated with varying concentrations of compound before the addition of 5 nM AMF-activated G\(_{\alpha}\). CCG-2046 and CCG-4986 inhibited with IC\(_{50} \) values of 4.3 \( \pm 0.2 \) and 4.2 \( \pm 0.1 \) \( \mu M \) \((n = 3)\), respectively.

**Fig. 3.** Inhibition of RGS4 GAP activity by CCG-4986. The two most potent compounds from our RGS4/G\(_{\alpha} \) binding screen were tested in single-turnover GTPase assays: 200 nM G\(_{\alpha} \) was loaded with a 3-fold molar excess of \([\text{32P}]\)GTP in 20 mM HEPES and 20 mM EDTA, pH 8.0, for 5 min at RT and then cooled on ice. This was then added to equal volumes of ice-cold initiation buffer (20 mM HEPES, 40 mM MgCl\(_2\), and unlabeled GTP, pH 8.0) containing RGS4 inhibitor (50 nM RGS4, 10 \( \mu M \) inhibitor, final). The reaction was quenched with 5\% activated charcoal (in 20 mM sodium phosphate, pH 2.0), incubated for 20 min, centrifuged, and the supernatant was counted using Cerenkov counting. The amount of \([\text{32P}]\)Pi released at each time point was fit to an exponential function: counts(t) = counts (t = 0) + \( \Delta \)counts (t = 30 min) \( \times (1-e^{-kt}) \). Whereas CCG-2046 did not inhibit this activity, CCG-4986 did significantly. The 68\% inhibition of the RGS GAP activity rate seen at 10 \( \mu M \) CCG-4986 \((n = 5, \text{ in triplicate})\) is consistent with the 3 to 4 \( \mu M \) IC\(_{50} \) value seen in FCPIA.
either the RGS or the Go subunit. CCG-4986 did not affect baseline GTPase activity or the binding of BODIPY-FL-GTPyS to Go (data not shown), suggesting that it was acting on the RGS. To determine whether CCG-4986 bound directly to RGS4, we examined the intrinsic fluorescence of RGS4, which has two tryptophan residues. An alteration of the environment surrounding the tryptophan(s) by direct interaction with the compound or conformational change upon compound binding could produce a change in net RGS4 fluorescence. CCG-4986 caused a concentration-dependent quenching of RGS4 intrinsic fluorescence (Fig. 4). The fluorescence was quenched 38% at 30 μM CCG-4986. This magnitude of quenching of RGS4 intrinsic fluorescence by CCG-4986 provides a notably robust signal. The addition of DMSO (vehicle) to RGS4 caused less than 10% quenching, and CCG-4986 did not alter the fluorescence of a solution of L-tryptophan, showing that the effect of CCG-4986 was dependent on the RGS4 structure and was not a spectral artifact such as absorption of excitation or emission light.

**Effect of CCG-4986 on Gaαi/o-Mediated Signaling.** A key test for any inhibitor of a protein-protein interaction is its ability to inhibit a signaling cascade that involves those proteins. To assess this activity of CCG-4986, we used a permeabilized cell adenyl cyclase (AC) assay, which measures accumulated cAMP as a readout (Clark et al., 2004). In these experiments, C6 glioma cells stably expressing the Goαi/o-coupled μ-opioid receptor were permeabilized with digitonin, and exogenous purified RGS4 protein was added to the system. Figure 5 shows the effect of forskolin, a direct AC activator, on the accumulation of cAMP. The addition of DAMGO, a μ-opioid agonist, decreases cAMP accumulated via Goαi/o-mediated inhibition of AC. The addition of 1 μM RGS4 “rescues” the AC from inhibition by Goαi/o, by accelerating the deactivation (GTP hydrolysis) of the α subunit, returning it to the inactive, GDP-bound form. The addition of CCG-4986 reverses the RGS4-mediated inhibition of the opioid response. This is an effect on RGS4, because CCG-4986 did not have any effect on the forskolin or DAMGO responses.

**CCG-4986 Selectively Inhibits RGS4.** The experiments described thus far demonstrate that CCG-4986 interacts directly with RGS4 and inhibits RGS4 activity; however, its specificity for RGS4 is not known. Based on shared sequence identity, RGS8 is the RGS most closely related to RGS4 (76% similar). Therefore, we tested the effect of CCG-4986 on Gaαi/RS8 binding by FCPIA (Fig. 6A), and it did not significantly effect the binding of RGS8 to Gaαi in contrast to its complete inhibition of Gaαi binding to RGS4. We then tested CCG-4986 on RGS8 functional activity in the permeabilized cell cyclase assay. Even at 30 μM, CCG-4986 did not significantly inhibit the activity of RGS8 on μ-opioid suppression of cAMP accumulation (Fig. 6B).

**Purity and Activity of CCG-4986.** In the course of this study, three batches of CCG-4986 were obtained from Chembridge. The batches of CCG-4986 showed identical activity for inhibiting RGS4. The purity of CCG-4986 was determined by analytical high-performance liquid chromatography to be ~96%. To ensure that the RGS4 inhibitory activity was from the reported structure of CCG-4986, semipreparative high-performance liquid chromatography was used to separate the major compound component (~96%) from a minor contaminant. Subsequent FCPIA experiments showed that the RGS4 inhibitory activity was contained within the major component, and the minor impurity showed no activity. The resolved components were subject to direct infusion mass spectrometry, and the major peak showed an m/z of 374.9, consistent with the structure of CCG-4986.

**Discussion**

Most high-affinity inhibitors of protein-protein interactions target protein pairs in which one protein displays a small peptide that is buried in a relatively well-defined binding pocket on its cognate binding partner. Examples include both peptide and small-molecule inhibitors for a subset of protein interactions, such as Bcl-2 and Bak-BH3 domains (Degterev et al., 2001), Myc/Max dimerization (Berg et al., 2002), and p53/mdm2 interaction (Duncan et al., 2001; Stoll

---

**Fig. 4.** Quenching of RGS4 intrinsic fluorescence by CCG-4986. Intrinsic tryptophanyl fluorescence of RGS4 (2 μM) was measured using a spectrofluorometer. The addition of CCG-4986 quenched the intrinsic fluorescence in a concentration-dependent manner, with a maximal inhibition of 38% and an IC50 value of 10.7 ± 0.7 μM (n = 3). The addition of DMSO as a control had a minimal effect on the RGS4 intrinsic fluorescence. The addition of CCG-4986 to a solution of 1 μM L-tryptophan did not affect the fluorescence of the free L-tryptophan.

**Fig. 5.** Inhibition of RGS4 activity by CCG-4986 in permeabilized cells. C6 glioma cells stably expressing μ-opioid receptors were assayed for cAMP accumulation under various conditions. Data are expressed as a percentage of the forskolin-stimulated cAMP production and are from three to five independent experiments. Forskolin (10 μM) stimulates the production of cAMP, which is inhibited by the μ-opioid agonist DAMGO (100 nM) through Goαi subunits. The addition of 1 μM RGS4 reverses the DAMGO-mediated inhibition. The activity of CCG-4986 on RGS4 is reflected by the increase in accumulated cAMP as RGS4 is inhibited.
et al., 2001). These types of interactions are amenable to very high throughput assays using fluorescence polarization measurements of a labeled peptide combined with its protein binding partner (Nikolovska-Coleska et al., 2004). However, many protein-protein interactions cannot be easily studied by fluorescence polarization, either because the exact interaction interface is unknown or the contact surface lacks a discrete, isolated peptide binding domain and is instead a rather flat, large surface. Such is the case for the Go/RGS interaction. FCPIA is ideally suited for examining these types of protein-protein interactions. The nanomolar concentrations of protein necessary and excellent signal-to-noise ratio translate into an assay that is suitable even for protein pairs, which may be difficult to express or purify in large quantity. Whereas the throughput of flow cytometry has in the past not been very high, the availability of commercial 96-well plate-reading flow cytometry systems (e.g., Luminex) has improved this situation with the capability of reading a plate in less than 30 min. In addition, the Hypercyt system developed by Sklar and colleagues (Young et al., 2005) is reported to collect flow cytometry data as fast as 2.5 min per 96-well plate, making this approach truly viable for high-throughput screening.

In our screen we identified two compounds (CCG-4986 and CCG-2046) as primary screening hits. It is surprising that our other high-potency compound (CCG-2046) did not inhibit activity of RGS4 at Go, despite its potency in the FCPIA interaction assay. It is possible that CCG-2046 had spectral interference effects, but it did not inhibit RGS8 binding to Go in FCPIA (data not shown), which makes that unlikely. There are differences in the conditions of the GAP assay and the FCPIA assay. The latter uses GDP/aluminum-magnesium-fluoride instead of GTP so either an interaction with the AMF or an effect that is specific to the transition-state could contribute.

The major advance in this study is the identification of the first small-molecule inhibitor of an RGS protein, CCG-4986. It has good potency (IC_{50} < 10 μM) for a primary screening hit. It has a molecular weight of 374.8 and a log P of 3.14, which are well within the range of active drugs. Efforts to establish the site of contact of CCG-4986 with RGS4 and to define initial structure-activity relations to enhance potency are underway. Although it is active in vitro, preliminary results in intact RGS4-transfected cells did not show activity (data not shown), suggesting that it may not be cell-permeable. This may be due to the relatively high topological polar surface area (130, calculated with the Chemaxon Marvin plug-in), which predicts difficulty crossing membranes. Thus, optimization of the structure for intact cell-based studies may be needed. Regardless, our primary screening hit CCG-4986 should prove to be a useful molecular tool for understanding the role and specificity of RGS4 and will serve as a first example defining an “RGS pharmacology.”

It is intriguing to speculate on potential applications of RGS inhibitors. In Parkinson’s disease, RGS9-2 has been identified as being overexpressed in the striatum of levodopa-treated patients (Tekumalla et al., 2001). Inhibiting its GAP activity, which terminates Go signaling in dopaminergic neurons (Rahman et al., 1999), could be useful to enhance dopamine signaling (Neubig and Siderovski, 2002). It is interesting that a recent study by Ding et al. (2006) showed effects of RGS4 on M_{2} muscarinic autoreceptor function leading to increased levels of striatal acetylcholine, which could be detrimental in Parkinson’s. This recent discovery presents a model system in which an RGS4 inhibitor could be useful for both studying the signaling phenomena in the laboratory and providing an initial step toward therapeutics.

The search for RGS inhibitors and protein-protein interaction inhibitors in general provides exciting opportunities for targeting novel steps in signal-transduction pathways. This can provide valuable information about pathway functions and provides a marked increase in the number of potential pharmacological targets. This discovery of the first small-molecule RGS4 inhibitor represents a first step to chemical targeting of this novel aspect of GPCR signaling. In addition, the FCPIA screening approach may be useful in identifying additional protein-protein interaction inhibitors to aid the study of the complex protein interaction inhibitors to aid the study of the complex protein interaction signaling nexus found within cells.

**Fig. 6.** Specificity of CCG-4986 for RGS4. A, the effect of CCG-4986 on RGS binding to Go in the FCPIA assay. CCG-4986 inhibits RGS4 binding to Go in a dose-dependent manner but did not affect the ability of RGS8 to bind Go even at 100 μM (n = 3). B, effect of CCG-4986 on RGS activity in the permeabilized C6 cell assay (see Fig. 5). The activity of 1 μM RGS4 or RGS8 was measured in the absence or presence of 30 μM CCG-4986. 1 μM RGS4 reduced opioid inhibition by 89 ± 2% and RGS8 by 83 ± 5%. In contrast to the elimination of the effect of RGS4, CCG-4986 did not significantly inhibit the activity of RGS8 (n = 3).
Identification of Small-Molecule Inhibitors of RGS4


Address correspondence to: Dr. Richard B. Neubig, University of Michigan Medical School, Department of Pharmacology, 1150 W. Medical Center Drive, 1303 MSRB III, Ann Arbor, MI 48109. E-mail: rneubig@umich.edu